Dachengqi decoction
PreclinicalSmall molecule
Dachengqi decoction is one of 6 small molecule programs targeting Gastrointestinal. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Gastrointestinal
#DrugCompanyPhaseTrials
1Movantik
AAveritas Pharma, Inc.
Phase 3
Cytalux
OOn Target Laboratories, LLC
Phase 3
Octreotide
Johnson & JohnsonPreclinical
Mosapride Citrate
IlDong Pharmaceutical Co LtdPreclinical
Dachengqi decoction
XXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Preclinical
Buscopan
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Gastrointestinal1 trial
Dachengqi Decoction for Enhancing Early Gastrointestinal Recovery After Whipple Surgery
Active, not recruiting·—·N/A·NCT06948474·45 enrolled
Hypertension1 trial
The Study of Dachengqi Decoction Combined With Probiotic L92 to Improve the Prognosis of Patients With Severe Abdominal Hypertension
Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2/3·NCT04517045·752 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dachengqi decoction. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details